“TREMFYA is the first and only IL-23 inhibitor that offers a fully subcutaneous treatment option for moderately to severely active Crohn’s disease. With the approval of TREMFYA, it is now ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s ...

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth. In a new podcast, web editor Nicole Raleigh speaks ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...

Twenty-four-week results showed Tremfya reduced signs, symptoms and structural progression of the disease. Perspective from Anthony P. Fernandez, MD, PhD Tremfya reduced signs and symptoms of ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

Johnson & Johnson (J&J) has announced that Stelara (ustekinumab) has been approved by the European Commission (EC) to treat moderately to severely active Crohn’s disease (CD ... comes just days after ...